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without	secondarily	generalization	and	in	the	US	as	a	monotherapy	or	
adjunctive	 treatment	 of	 partial-	onset	 seizures	 (Aptiom®;	Zebinix®).	
ESL	is	a	third-	generation	member	of	the	dibenzazepine	family,	which	
also	includes	carbamazepine	(CBZ)	and	oxcarbazepine	(OXC;	Keating,	
2014;	 Zaccara,	 Giovanelli,	 Cincotta,	 &	 Verrotti,	 2015).	 Blockade	 of	
voltage-	gated	 sodium	 channel	 (VGSC)	 is	 the	 proposed	 mechanism	
of	action	 for	CBZ,	OXC,	and	ESL	 (Keating,	2014),	but	ESL	has	been	
shown	 to	have	a	modulating	action	and	 inhibits	 the	 slow	activation	
of	VGSC	 (Hebeisen	et	al.,	2015)	and	also	an	effect	on	Cav3.2T-	type	
Ca2+	channels	(Doeser	et	al.,	2015).	ESL	is	a	prodrug	that	is	metabo-






concentrations	 of	 ESL	were	 reached	 in	median	 2.0–2.5	hr	 (Almeida	
&	Soares-	Da-	silva,	2004).	Steady	state	is	reached	in	4–5	days	(Elger,	
Halász,	Maia,	Almeida,	&	Soares-	Da-	silva,	2009).
Eslicarbazepine	 acetate	 is	 efficacious	 and	 well	 tolerated	 as	 ad-
junctive	therapy	in	drug-	resistant	focal	epilepsies	at	doses	of	800	and	
1,200	mg	once-	daily	 (Ben-	Menachem	et	al.,	2010;	Elger	et	al.,	2009;	
Gil-	Nagel,	 Lopes-	Lima,	Almeida,	Maia,	&	 Soares-	Da-	silva,	 2009;	Gil-	
Nagel	et	al.,	2013;	Sperling	et	al.,	2015).	Dizziness,	vertigo,	abnormal	






(Villanueva	et	al.,	 2014).	Recent	meta-	analysis	 compared	 the	 tolera-
bility	of	ESL,	OXC,	and	lacosamide	(LCM)	showing	that	patients	with	
OXC	withdrew	from	the	treatment	more	frequently	than	patients	with	




8.8%	between	different	 studies	 (Halasz	et	al.,	 2010;	Hufnagel	 et	al.,	
2013;	 Villanueva	 et	al.,	 2014;	 Zaccara	 et	al.,	 2013).	 The	 difference	
can	be	explained	in	terms	of	dosage	used,	population	characteristics,	
and	 cut-	off	 used	 to	 define	 hyponatremia.	 These	 data	 suggest,	 that	
ESL	might	share	similar	efficacy	compared	to	OXC,	but	with	less	AEs.	


















2  | MATERIAL AND METHODS
We	 identified	all	 the	patients	 (age	at	 least	18	years)	with	 focal	epi-
lepsy	followed	in	the	Department	of	Neurology	in	Tampere	University	




and	 (4)	 transition	was	 undertaken	 before	 30	November	 2015.	 The	
dosages	of	concomitant	AEDs	remained	unchanged	during	the	transi-
tion	period.	All	subjects	were	on	immediate-	release	OXC	as	extended-	
release	OXC	 is	 not	 available	 in	 Finland.	 Information	 on	 the	 patient	
characteristics	was	obtained	retrospectively	from	the	medical	records.
Tolerability	 problems	 related	 to	OXC	were	 categorized	 as	 in	 re-
cent	meta-	analysis	(Zaccara	et	al.,	2013)	addressing	neurological	AEs	
of	 new	 generation	 sodium-	blockers	 (somnolence,	 dizziness,	 vertigo,	
ataxia/coordination	 abnormal,	 diplopia,	 nystagmus,	 fatigue,	 tremor,	
headache,	 nausea,	 vomiting).	 Patients	 were	 classified	 according	 to	
ILAE	guidelines	to	temporal,	 frontal,	parietal,	occipital,	multifocal,	or	
unclassifiable	 epilepsies	 based	 on	 seizure	 characteristics,	 EEG	 and	
imaging	findings	and	for	some	patients	on	ictal	video-	EEG	recordings	
(CoCaTotILA,	 1989).	The	 etiologies	were	 divided	 into	 remote	 symp-
tomatic	and	unknown.	The	seizure	frequency	from	the	previous	year	
was	recorded;	seizure-	free	patients	did	not	have	any	seizures	during	














moderate,	 severe)	were	 recorded	and	 reported	 following	 the	 transi-
tioning	period.	Mild	was	defined	as	 a	 symptom	not	 interfering	with	
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This	was	a	noninvasive,	retrospective	study,	which	does	not	oblige	






because	 of	 OXC-	related	 AEs.	 Demographic	 and	medical	 character-
istic	 of	 the	 subjects	 are	 presented	 in	 Table	1.	 Three	most	 common	





spect	 to	 their	 persistency	was	 analyzed	 and	 the	 results	 are	 shown	
in	Figure	2.	Two	 thirds	 (66.5%)	of	 the	AEs	occurred	 in	 the	morning	




dizziness,	 and	 diplopia.	 Fatique,	 somnolence,	 tremor,	 diplopia,	
and	nausea	mostly	resolved	after	transition.	A	clear	tendency	that	
some	AEs	would	have	been	more	persistent	than	others,	especially	
in	 the	morning,	was	 not	 observed.	However,	 dizziness	 and	 coor-
dination	 problems	were	 the	 commonest	AEs	 that	 persisted	 after	 
transition.
The	effects	of	the	transition	from	OXC	to	ESL	on	seizure	frequency	
are	 summarized	 in	Table	2.	AEs	 occurring	 after	 transition	 related	 to	
ESL	are	shown	in	Figure	3.	The	incidence	of	AEs	was	higher	at	1	month	
(39.1%	[9/23])	than	at	3	month	follow-	up	(13.0%	[3/23]).	However,	no	




Changes	 in	 seizure	 frequency	 or	 duration	 were	 not	 observed	
during	 the	 transition	 period	 in	 a	 hospital	 inpatient	 setting.	Two	pa-
tients	 reported	 headache	 during	 the	 hospitalization,	 but	 at	 1	 and	






























































concentration	 as	 suggested	 earlier	 (Keating,	 2014).	 These	 findings	
might	help	clinician	in	everyday	practice	to	assess	whether	patient’s	
complaints	of	neurological	AEs	related	to	OXC,	especially	in	complex	
situations;	 several	 AEDs,	 comorbidities	 (e.g.	 depression,	 sleeping	
problems)	and,	persistent	seizures.
The	 secondary	 objective	was	 to	 assess	 the	 efficacy	 of	 ESL.	The	
results	 of	 this	 study	 indicated	 that	 when	 switched	 from	 OXC,	 ESL	
was	effective	 and	well	 tolerated	during	3	months	 follow-	up.	During	
previous	year	12	patients	had	persistent	seizures	and	after	changing	
from	OXC	to	ESL	 in	one	patient	 seizure	 frequency	 reduced	by	50%	
and	in	another	patient	by	30%.	Moreover,	in	two	patients	seizure	du-
ration	shortened	without	change	in	seizure	frequency.	Altogether	four	





ations	 in	which	 it	may	be	 reasonable	 to	convert	patients	 from	OXC	






lated	or	other	problems	during	 the	 transition	 in	 any	of	our	patients	
which	 give	 added	 value	 to	 the	 publication	 by	 Schmid	 et	al.	 (2016).	




Baseline SF (previous 
month) 1st month SF 2nd month SF 3rd month SF Outcome
1–11 Seizure	free No	seizures No	seizures No	seizures Still	seizure	free
12 1	SGS,	31	SPS,	4	CPS 30	SPS,	3	CPS 32	SPS,	4	CPS 31	SPS,	6	CPS No	significant	change	in	SF
13 Infrequent	seizuresa No	seizures No	seizures No	seizures No	significant	change	in	SF
14 1	SGS,	5	CPS 2	CPS No	seizures 1	CPS 50%	reduction	in	seizure	frequency
15 1	SPS,	2	CPS 2	SPS,	2	CPS 1	SPS,	3	CPS 1	SPS,	2	CPS No	significant	change	in	SF
16 83	SPS,	8	CPS 84	SPS,	8	CPS 83	SPS,	8	CPS 83	SPS,	8	CPS No	change	in	SF
17 5	CPS 4	CPS 5	CPS 6	CPS No	change	in	SF,	seizure	duration	shortened
18 1	CPS No	seizures 1	CPS No	seizures 30%	reduction	in	seizure	frequency
19 Infrequent	seizuresb No	seizures No	seizures No	seizures No	significant	change	in	SF







22 2	SGS,	7	CPS 3	SGS,	8	CPS 2	SGS,	11	CPS 3	SGS,	6	CPS No	significant	change	in	SF
































whereas	 in	our	center	the	 last	 intake	of	OXC	was	the	morning	dose	
followed	by	the	first	intake	of	ESL	already	in	the	evening	of	the	same	
day.	There	were	no	differences	between	 these	 two	 studies	on	how	
the	initiation	of	ESL	was	performed	in	terms	of	target	dosing	as	both	
studies	aspired	to	use	a	ratio	of	1:1	of	OXC	and	ESL.
Considering	 the	 limitations,	 this	 was	 retrospective	 uncontrolled	
follow-	up	 study	 and	 the	 relative	 number	 of	 our	 patient	 is	 not	 high.	
However,	when	considering	the	results	and	conclusions	emerging	from	








rently	 receiving	OXC	and	 experiencing	 intolerable	AEs	 benefit	 from	












honoraria	 from	 Boehringer-	Ingelheim;	 received	 research	 fund-
ing	 from	 Finnish	 Epilepsy	 Association;	 and	 participated	 in	 advisory	
board	for	Eisai.	Sirpa	Rainesalo	has	received	speaker	honoraria	from	
FennoMedical,	Orion	Pharma,	UCB	and	received	support	for	travel	to	
congresses	 from	Abbvie	and	UCB.	 Jukka	Peltola	has	participated	 in	
clinical	 trials	 for	Eisai,	UCB,	and	Bial;	 received	 research	grants	 from	
Eisai,	Medtronic,	 UCB,	 and	 Cyberonics;	 received	 speaker	 honoraria	
from	Cyberonics,	Eisai,	Medtronic,	Orion	Pharma,	and	UCB;	received	
support	 for	 travel	 congresses	 from	 Cyberonics,	 Eisai,	 Medtronic,	
and	UCB;	 and	participated	 in	 advisory	boards	 for	Cyberonics,	Eisai,	
Medtronic,	UCB,	and	Pfizer.
REFERENCES
Almeida,	 L.,	 &	 Soares-Da-silva,	 P.	 (2004).	 Safety,	 tolerability,	 and	 phar-
macokinetic	 profile	 of	 BIA	 2-	093,	 a	 novel	 putative	 antiepileptic,	 in	
a	 rising	 multiple-	dose	 in	 young	 healthy	 humans.	 Journal of Clinical 
Pharmacology,	44,	906–918.
Almeida,	 L.,	 &	 Soares-Da-silva,	 P.	 (2007).	 Eslicarbazepine	 acetate	 (BIA	
2-	093).	 Neurotherapeutics: The Journal of the American Society for 
Experimental NeuroTherapeutics,	4,	88–96.
Aptiom®.	Prescribing Information.	 (2013).	 Retrieved	 from	http://www.ap-
tiom.com/Aptiom-Prescribing-Information.pdf









Elger,	 C.,	 Halász,	 P.,	 Maia,	 J.,	 Almeida,	 L.,	 &	 Soares-Da-silva,	 P.	 (2009).	






















3 months 1 month
6 of 6  |     MÄKINEN Et al.
eslicarbazepine	 acetate	 as	 adjunctive	 treatment	 in	 adults	 with	
	refractory	 partial-	onset	 seizures:	 A	 randomized,	 double-	blind,	
placebo-	controlled,	parallel-	group	phase	 III	study.	Epilepsia,	50,	454– 
463.





Gil-Nagel,	 A.,	 Lopes-Lima,	 J.,	 Almeida,	 L.,	 Maia,	 J.,	 &	 Soares-Da-silva,	 P.	
(2009).	BIA-	2093-	303	Investigators	Study	Group.	Efficacy	and	safety	





















junctive	 therapy	 in	 refractory	 partial-	onset	 seizures.	CNS Drugs,	 28,	
583–600.





P.	 (2011).	 Pharmacokinetics	 of	 eslicarbazepine	 acetate	 at	 steady-	
state	in	adults	with	partial-	onset	seizures.	Epilepsy Research,	96,	132– 
139.
Sander,	 J.	 W.	 (2003).	 The	 epidemiology	 of	 epilepsy	 revisited.	 Current 
Opinion in Neurology,	16,	165–170.
Schmid,	 E.,	 Kuchukhidze,	 G.,	 Kirschner,	 M.,	 Leitinger,	 M.,	 Höfler,	 J.,	
Rohracher,	 A.,	 …	 Trinka,	 E.	 (2016).	 Overnight	 switching	 from	 oxcar-
bazepine	 to	 eslicarbazepine	 acetate:	 An	 observational	 study.	 Acta 
Neurologica Scandinavica.	doi:10.1111/ane.12645
Sperling,	 M.	 R.,	 Abou-Khalil,	 B.,	 Harvey,	 J.,	 Rogin,	 J.	 B.,	 Biraben,	 A.,	
Galimberti,	 C.	 A.,	 …	 Soares-da-Silva,	 P.	 (2015).	 Eslicarbazepine	 ace-
tate	as	adjunctive	therapy	in	patients	with	uncontrolled	partial-	onset	
seizures:	 Results	 of	 a	 phase	 III,	 double-	blind,	 randomized,	 placebo-	
controlled	trial.	Epilepsia,	56,	244–253.
Stephen,	L.	J.,	&	Brodie,	M.	J.	(2012).	Antiepileptic	drug	monotherapy	ver-
sus	 polytherapy:	 Pursuing	 seizure	 freedom	and	 tolerability	 in	 adults.	
Current Opinion in Neurology,	25,	164–172.
Striano,	 S.,	 Striano,	 P.,	 Di	 Nocera,	 P.,	 Italiano,	 D.,	 Fasiello,	 C.,	 Ruosi,	 P.,	
…	 Pisani,	 F.	 (2006).	 Relationship	 between	 serum	 mono-	hydroxy-	
carbazepine	 concentrations	 and	 adverse	 effects	 in	 patients	with	 ep-







ity	of	eslicarbazepine:	Current	evidence.	Drug Design, Development and 
Therapy,	9,	781–789.
Zaccara,	 G.,	 Giovanelli,	 F.,	 Maratea,	 D.,	 Fadda,	 V.,	 &	 Verrotti,	 A.	 (2013).	
Neurological	adverse	events	of	new	generation	sodium	blocker	antie-
pileptic	 drugs.	 Meta-	analysis	 of	 randomized,	 double-	blinded	 studies	
with	 eslicarbazepine	 acetate,	 lacosamide	 and	 oxcarbazepine.	Seizure,	
22,	528–536.
Zebinix®.	 Summary of product characteristics.	 (2012).	 Retrieved	 from	
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/000988/WC500047225.pdf
How to cite this article:	Mäkinen	J,	Rainesalo	S,	Peltola	J.	
Transition	from	oxcarbazepine	to	eslicarbazepine	acetate:	
A	single	center	study.	Brain Behav. 2017;7:e00634.  
https://doi.org/10.1002/brb3.634
